Market Place
Sourcing Support
Tiziana Life Sciences Appoints New Chief Executive Officer
19 Aug 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences Regains Nasdaq Compliance With Minimum Bid Price Rule
14 Aug 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences Granted FDA Fast Track Designation
24 Jul 2024 //
GLOBENEWSWIRE
Tiziana Receives $3.4 Million in Non-Dilutive Funding
28 Jun 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences To Dose First Alzheimer`s Patient
26 Jun 2024 //
GLOBENEWSWIRE
FDA Accepts Tiziana Life Fast Track Designation Submission for Treatment of MS
11 Jun 2024 //
GLOBENEWSWIRE
Tiziana: 80% MS Patients Showed 6-Month Neuroimaging Improvement With Foralumab
06 Jun 2024 //
GLOBENEWSWIRE
Tiziana: ALS Grant For Intranasal Foralumab Clinical Trial
04 Jun 2024 //
GLOBENEWSWIRE
Tiziana Board Chair To Receive MS Research Award
30 May 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
13 May 2024 //
GLOBENEWSWIRE
Tiziana Reports Positive MS Foralumab Neuroimaging at 3 Months
25 Apr 2024 //
GLOBENEWSWIRE
Tiziana Gets FDA Approval for More MS Foralumab Patients
23 Apr 2024 //
GLOBENEWSWIRE
Tiziana`s MS Patients Show More Expanded Access Improvements
22 Apr 2024 //
GLOBENEWSWIRE
Tiziana: Foralumab MS Data With PIRA Highlighted In Neurology Today
19 Apr 2024 //
GLOBENEWSWIRE
Tiziana: New Quantitative PET Data On Foralumab At AAN 2024
18 Apr 2024 //
GLOBENEWSWIRE
Tiziana PET Imaging Data On Foralumab At AAN
11 Apr 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Podium Presentation
05 Mar 2024 //
GLOBENEWSWIRE
Tiziana Announces Updated Clinical and PET Scan Findings for Foralumab
08 Jan 2024 //
GLOBENEWSWIRE
Tiziana Life Files New Patent Application for Combination Therapy of anti-CD3
05 Jan 2024 //
GLOBENEWSWIRE
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco
05 Jan 2024 //
GLOBENEWSWIRE
Tiziana Life Doses First Patient in Phase 2a Trial of Intranasal Foralumab
19 Dec 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients
30 Nov 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich
01 Nov 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Foralumab
18 Oct 2023 //
GLOBENEWSWIRE
Tiziana Announces Positive Six-Month PET Scan Results With Intranasal Foralumab
13 Oct 2023 //
GLOBENEWSWIRE
Tiziana Announces Presentation of Six-Month Safety Data for Foralumab
11 Oct 2023 //
GLOBENEWSWIRE
Tiziana Life Initiates Multi-Center Phase 2a Trial of Intranasal Foralumab
26 Sep 2023 //
GLOBENEWSWIRE
Tiziana Life to Participate in H.C. Wainwright 25th Annual Investment Conference
08 Sep 2023 //
GLOBENEWSWIRE
Study Validating MoA of Intranasal Foralumab in Alzheimer™s Disease Published
06 Sep 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner
23 Aug 2023 //
GLOBENEWSWIRE
Tiziana Appoints William A. Clementi as Chief Development Officer
23 Aug 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab
15 Aug 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
21 Jul 2023 //
GLOBENEWSWIRE
Tiziana Life Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
13 Jun 2023 //
GLOBENEWSWIRE
Tiziana Announces Reduction in Microglial Activation in Intranasal Foralumab
05 Jun 2023 //
GLOBENEWSWIRE
Tiziana Life to Host KOL Webinar on Foralumab in Non-Active SPMS
25 May 2023 //
GLOBENEWSWIRE
Tiziana Announces Participation on Webull Corporate Communications Platform
23 May 2023 //
GLOBENEWSWIRE
Tiziana Life Announces CMO Invited to Give Presentation on Foralumab
17 May 2023 //
GLOBENEWSWIRE
Tiziana Announces Findings from Anti-CD3 mAb
27 Apr 2023 //
PRESS RELEASE
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months
26 Apr 2023 //
GLOBENEWSWIRE
Tiziana Life Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
24 Apr 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences File Alzheimerâ IND for Intranasal Foralumab in Q2 2023
20 Apr 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Initiates Program to Dep Intranasal Foralumab T1 Diabetes
18 Apr 2023 //
GLOBENEWSWIRE
Tiziana to Pursue Development of Intranasal Foralumab
13 Apr 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Presentations on Intranasal Foralumab at the Conference
10 Apr 2023 //
GLOBENEWSWIRE
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody
04 Apr 2023 //
GLOBENEWSWIRE
Tiziana Announces Invitation for Presentation on Anti-CD3 mAb
04 Apr 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Announces Anti-CD3 mAb Research for Alzheimer’s Disease
31 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life to Proceed with PII Trial in Patients with Non-Active SPMS
28 Mar 2023 //
GLOBENEWSWIRE
Tiziana Announces Purchase of Common Shares by Chairman and Acting CEO
22 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Purchase of Common Shares by Chairman and Acting CEO
21 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Purchase of Common Shares by Chairman and Acting CEO
20 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Highlighted in Forbes Article
17 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Purchase of Common Shares by Chairman and Acting CEO
17 Mar 2023 //
GLOBENEWSWIRE
Tiziana Announces Publication in PNAS Illustrating Intranasal Foralumab
08 Mar 2023 //
GLOBENEWSWIRE
Tiziana Life Announces IND filed for Phase 2 of Milciclib with Gemcitabine
04 Jan 2023 //
GLOBENEWSWIRE
Tiziana Life Announces Additional Clinical Improvements in Second Patient
03 Jan 2023 //
GLOBENEWSWIRE
Tiziana Life Sciences Updated Interim Results for the 6 Months Ended 30 June
29 Dec 2022 //
GLOBENEWSWIRE
Tiziana Life Sciences Interim Results for the Six Months Ended 30 June 2022
27 Dec 2022 //
GLOBENEWSWIRE
